Michael D. Ezekowitz , MB, ChB, DPhil

Photo of Michael Ezekowitz

Photo of Michael Ezekowitz

LIMR Job Title:  Professor & Vice President

Email: EzekowitzM@mlhs.org

Phone: 484-476-8451

Fax: 610-645-4623

Office: G36A

Department: Clinical Research

Association: Resident Faculty

Other Appointment: Vice President, Clinical Research, Main Line Hospitals6

Education

  • M.B.,Ch,B (equivalent to M.D.), University of Cape Town, Cape Town, South Africa, 1970
  • D. Phil., Imperial College, London University, 1976
  • Fellow, Cardiology, Johns Hopkins Hospital, Baltimore, MD, 1976-1978

Current Appointments

  • 2005 to present: Professor & Vice President, Lankenau Institute for Medical Research, Vice President, Clinical Research, Main Line Hospitals
  • 2005 to present: Attending Cardiologist, Lankenau, Bryn Mawr & Paoli Hospitals

Research Interests

  • Design and conduct clinical trials, stroke prevention, thrombosis and atrial fibrillation

Personnel

  • Amit Parekh, MD, Clinical Research Physician
  • Haris Usman, MD, Clinical Research Physician
  • Sabreen Raza, Clinical Research Associate
  • Michael Chernick, PhD, Manager, Biostatistical Services
  • John Wellenbach, Clinical Business Manager
  • Judith R. Spahr, Clinical Trials Coordinator
  • Ellen Bedenko, RN, Clinical Trials Nurse Coordinator
  • Paulette Trent, Executive Assistant
  • Daphne Geathers, Administrative Assistant/Analyst

Awards and Honors:

  • British Council Fellowship
  • Honorary Degree, Fellow of Royal College of Physicians
  • Honorary Degree, MA, Yale University School of Medicine

Clinical: Active clinical cardiologist. Interest in atrial fibrillation.

Research Summary:


Dr Ezekowitz is an internationally known cardiologist with special expertise in echocardiology, thrombosis and atrial fibrillation. He has published over 300 peer-reviewed articles and book chapters. Dr Ezekowitz's basic work has been funded from the NIH and Veterans Administration and he has designed several large clinical trials. One of his most highly cited articles, published in the New England Journal of Medicine (1992), proved that the blood thinning agent Coumadin® protected patients from stroke who had atrial fibrillation. The current focus of Dr. Ezekowitz's research are experimental anti-coagulation and anti-arrhythmic drugs that may provide an important new option for patients that have difficulty with medical treatment with Coumadin® and current anti-arrhythmic agents.

  1. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA; American College of Chest Physicians. (2008). The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest;133(6 Suppl):776S-814S.
  2. Ezekowitz MD. Maintaining sinus rhythm--making treatment better than the disease. N Engl J Med. 2007 Sep 6;357(10):1039-41. 
  3. Ezekowitz MD, Nagarakanti R. , ""Challenges of establishing new antithrombotic therapies in atrial fibrillation"". Circulation. 2008 Feb 5;117(5):e149;
  4. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L. (2007). Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol.;100(9):1419-26.
  5. Parekh A, Jaladi R, Sharma S, Van Decker WA, Ezekowitz MD., Images in cardiovascular medicine. The case of a disappearing left atrial appendage thrombus: direct visualization of left atrial thrombus migration, captured by echocardiography, in a patient with atrial fibrillation, resulting in a stroke. (2006). Circulation; 114(13):e513-4.
  6. Patel B, Parekh A, Ezekowitz MD. Mortality after the hospitalization of a spouse (2006). N Engl J Med.;354(20):2190-1.
  7. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma, SC, Atwood JE, Jacobson AK, Lewis, Jr. HD, Raisch DW, and Ezekowitz MD for the Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. (2005). Amiodarone versus Sotalol for Atrial Fibrillation. N. Engl. J. Med. 352: 1861-1872.
  8. Michael D. Ezekowitz, M.B.,Ch.B.,D.Phil, F.R.C.P.,Letter to editor regarding article Dronedarone in Atrial Fibrillation. N ENGL J MED 2007; 357;23,2402-2405
  9. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P; Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group (2002). Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 105: 557-563. 
  10. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, et al. (1992). Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N. Engl. J. Med. 327: 1406-1412. 
 

Main Line Health

© 2010 Lankenau Institute for Medical Research. All rights reserved. | Terms of Use | Privacy Policy